Respiratory Syncytial Virus Pre-Fusion Glycoprotein F Mrna
drugOn this page
Also known as Mresvia
Summary
Respiratory Syncytial Virus Pre-Fusion Glycoprotein F Mrna (CHEMBL6068496) is an approved vaccine component; indicated across 2 conditions including respiratory syncytial virus infectious disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Vaccine component
- Indications: 2 conditions
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL6068496 |
| Name | Respiratory Syncytial Virus Pre-Fusion Glycoprotein F Mrna |
| Type | Vaccine component |
| Max phase | 4 |
Also known as: Mresvia
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| respiratory syncytial virus infectious disease | 4 | MONDO:0001577 | EFO:1001413 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).